# Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

> **NCT06461936** · — · ACTIVE_NOT_RECRUITING · sponsor: **Chen Xiaoping** · enrollment: 620 (actual)

## Conditions studied

- HCC
- Adjuvant Therapy
- Immunotherapy
- Recurrence

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06461936
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461936, "Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT06461936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*